We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$2.21M
Cap. Flow
-$39.8M
Cap. Flow %
-1.28%
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
26
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.7M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.2M
3
MRNA icon
Moderna
MRNA
+$25.5M
4
DHR icon
Danaher
DHR
+$16.7M
5
RMD icon
ResMed
RMD
+$15.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.3M
2
EXAS
Exact Sciences
EXAS
+$21.5M
3
CTLT
CATALENT, INC.
CTLT
+$19.2M
4
XRAY icon
Dentsply Sirona
XRAY
+$17.1M
5
CI icon
Cigna
CI
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Real Estate 2.82%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOLX
126
DELISTED
Hologic
HOLX
$2.17M 0.07%
28,347
– –
PRGO icon
127
Perrigo
PRGO
$1.48B
$1.99M 0.06%
51,224
– –
ITOS
128
DELISTED
iTeos Therapeutics
ITOS
$1.97M 0.06%
42,362
– –
ENDP
129
DELISTED
Endo International plc
ENDP
$1.86M 0.06%
494,607
– –
ACAD icon
130
Acadia Pharmaceuticals
ACAD
$4.39B
$1.69M 0.05%
+72,225
New +$1.45M
DTIL icon
131
Precision BioSciences
DTIL
$182M
$1.66M 0.05%
7,484
+5,384
+256% +$1.5M
MORF
132
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.66M 0.05%
35,025
– –
PYXS icon
133
Pyxis Oncology
PYXS
$193M
$1.48M 0.05%
+135,000
New +$1.55M
PRAX icon
134
Praxis Precision Medicines
PRAX
$8.52B
$1.48M 0.05%
5,000
– –
ZGNX
135
DELISTED
Zogenix, Inc.
ZGNX
$1.45M 0.05%
88,977
– –
ALXO icon
136
ALX Oncology
ALXO
$260M
$1.42M 0.05%
66,211
+59,112
+833% +$2.55M
DSGN icon
137
Design Therapeutics
DSGN
$797M
$1.4M 0.05%
+65,351
New +$1.12M
FULC icon
138
Fulcrum Therapeutics
FULC
$283M
$1.37M 0.04%
77,293
+33,395
+76% +$662K
MRUS
139
DELISTED
Merus
MRUS
$1.33M 0.04%
+41,857
New +$1.18M
CERE
140
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.33M 0.04%
+41,003
New +$1.45M
THRX
141
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1.27M 0.04%
+100,000
New +$1.51M
BEAM icon
142
Beam Therapeutics
BEAM
$2.67B
$1.26M 0.04%
+15,817
New +$1.35M
CYH icon
143
Community Health Systems
CYH
$412M
$1.18M 0.04%
88,335
-13,200
-13% -$166K
ACET icon
144
Adicet Bio
ACET
$86.4M
$1.11M 0.04%
+3,958
New +$679K
DHC
145
Diversified Healthcare Trust
DHC
$2.13B
$1.1M 0.04%
357,720
– –
EWTX icon
146
Edgewise Therapeutics
EWTX
$4.13B
$925K 0.03%
+60,550
New +$1.09M
TCRX icon
147
TScan Therapeutics
TCRX
$47.3M
$900K 0.03%
200,000
– –
ASRT
148
DELISTED
Assertio
ASRT
$895K 0.03%
27,372
– –
ICPT
149
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$848K 0.03%
52,067
– –
MOR
150
DELISTED
MorphoSys AG American Depositary Shares
MOR
$771K 0.02%
81,867
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tekla Capital Management held 188 positions worth $3.11B, up 0.07% from $3.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q4 2021 filing shows 16 new, 26 increased, 40 reduced and 17 closed positions. Its largest new stake was AMN Healthcare: 61,201 shares worth $7.49M. The largest sale was Biogen, an estimated $25.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2021 buy was AMN Healthcare: 61,201 shares worth $7.49M.
  • Tekla Capital Management added most to Pfizer in Q4 2021, an estimated $35.7M increase.
  • Tekla Capital Management's biggest Q4 2021 reduction was Biogen, cutting an estimated $25.3M.
  • Tekla Capital Management fully exited Exact Sciences in Q4 2021, selling an estimated $21.5M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $3.11B portfolio in Q4 2021.
  • Tekla Capital Management opened 16 new positions and closed 17 in Q4 2021.
  • Tekla Capital Management's portfolio value rose 0.07% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.